How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Implant Device for AFib Treatment Market
- By Device Type: Left Atrial Appendage Closure Devices, Atrial Fibrillation Ablation Catheters, Implantable Cardioverter Defibrillators (ICDs), Pacemakers with AFib Management Features, Electrophysiology Mapping Systems
- By Technology: Radiofrequency Ablation, Cryoablation, Laser Ablation, Ultrasound Ablation, Hybrid Ablation Techniques
- By End User: Hospitals, Cardiac Specialty Clinics, Ambulatory Surgical Centers, Electrophysiology Labs
- By Indication: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Long-standing Persistent Atrial Fibrillation
- By Procedure Type: Minimally Invasive Procedures, Open Heart Surgery Procedures
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Left Atrial Appendage Closure Devices leads By Device Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Implant Device for AFib Treatment Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Device Type 5
Technology 5
End User 4
Indication 3
Procedure Type 2
Companies profiled
Abbott Laboratories
Boston Scientific Corporation
Medtronic plc
Biosense Webster (a Johnson & Johnson company)
LivaNova PLC
MicroPort Scientific Corporation
Sorin Group (now part of LivaNova)
Biotronik SE & Co. KG
St. Jude Medical (acquired by Abbott)
CardioFocus Inc.
AtriCure Inc.
Penumbra Inc.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Boston Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Biosense Webster (a Johnson & Johnson company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →LivaNova PLC
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →MicroPort Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Sorin Group (now part of LivaNova)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Biotronik SE & Co. KG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →St. Jude Medical (acquired by Abbott)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →CardioFocus Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →AtriCure Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Penumbra Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Farapulse Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Corindus Vascular Robotics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Endosense SA
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$9,212M by 2033 · 7.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Left Atrial Appendage Closure Devices53.7
- Atrial Fibrillation Ablation Catheters8.5
- Implantable Cardioverter Defibrillators (ICDs)13.5
- Pacemakers with AFib Management Features7.5
- Electrophysiology Mapping Systems16.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,664M → $2,823M · 6.8%
Europe$1,160M → $2,212M · 8.4%
Asia Pacific$1,059M → $1,916M · 7.7%
Latin America$655.5M → $1,203M · 7.9%
Middle East and Africa$504.2M → $872.9M · 7.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.782026
7.782027
7.812028
7.812029
7.832030
7.832031
7.852032
7.872033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Abbott Laboratories13.2
- Boston Scientific Corporation17.6
- Medtronic plc14.5
- Biosense Webster (a Johnson & Johnson company)9.1
- LivaNova PLC12.9
- MicroPort Scientific Corporation4.6
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Device Type23.0%
Technology14.1%
End User27.6%
Indication11.1%
Procedure Type24.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.3
- Europe24.5
- Asia Pacific21.2
- Latin America13.3
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | 95 | 89 | 85 | 80 | 74 | 97 | 87 |
| Boston Scientific Corporation | 90 | 89 | 69 | 89 | 71 | 88 | 83 |
| Medtronic plc | 80 | 74 | 68 | 63 | 86 | 84 | 76 |
| Biosense Webster (a Johnson & Johnson company) | 72 | 81 | 75 | 69 | 62 | 60 | 70 |
| LivaNova PLC | 74 | 75 | 69 | 63 | 58 | 56 | 66 |
| MicroPort Scientific Corporation | 56 | 50 | 47 | 59 | 58 | 52 | 54 |
| Sorin Group (now part of LivaNova) | 50 | 44 | 64 | 44 | 45 | 55 | 50 |
| Biotronik SE & Co. KG | 57 | 48 | 41 | 35 | 60 | 56 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Abbott Laboratories
- Boston Scientific Corporation
- Medtronic plc
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Abbott Laboratories | ✓ | ✓ | ✓ | ◐ | ◐ | ◐ |
| Boston Scientific Corporation | ✓ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Medtronic plc | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Biosense Webster (a Johnson & Johnson company) | − | ✓ | ✓ | ✓ | ◐ | ◐ |
| LivaNova PLC | ◐ | ◐ | ◐ | − | − | − |
| MicroPort Scientific Corporation | − | − | − | ◐ | ◐ | − |
| Sorin Group (now part of LivaNova) | − | ◐ | ◐ | − | − | − |
| Biotronik SE & Co. KG | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories87
2Boston Scientific Corporation83
3Medtronic plc76
4Biosense Webster (a Johnson & Johnson company)70
5LivaNova PLC66
6MicroPort Scientific Corporation54
7Sorin Group (now part of LivaNova)50
8Biotronik SE & Co. KG50
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Abbott LaboratoriesBoston Scientific Corporation
Challenger2
Strong scale, closing on the leaders.
Medtronic plcBiosense Webster (a Johnson & Johnson company)
Contender1
Focused players with pockets of strength.
LivaNova PLC
Niche3
Specialists in a single segment or region.
MicroPort Scientific CorporationSorin Group (now part of LivaNova)Biotronik SE & Co. KG
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Device Type in North America, then scale across Implant Device for AFib Treatment Market — a $414M beachhead inside a $7.45B market.
Beachhead (SOM)$414Mobtainable near-term
Serviceable (SAM)$2.57Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Left Atrial Appendage Closure Devices
Best fit — highest urgency & budget in Device Type.
Economic buyer81 fit
Atrial Fibrillation Ablation Catheters
Strong fit — clear ROI and a fast path to value.
End user67 fit
Implantable Cardioverter Defibrillators (ICDs)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Device Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Technology & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel26%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Device Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Implant Device for AFib Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified20%
Evaluation12%
Closed-won6%
$20.1KCAC
$79KLTV
3.9:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Implant Device for AFib Treatment Market is a resilient opportunity — $1.73B by 2033, compounding at 4.4%.
TAM · 2025$1.23Btoday
TAM · 2033$1.73Bforecast
CAGR4.4%2027–2033
Cumulative$13.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.73BTotal addressable market
SAM$653MServiceable available market
SOM$120MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.4% CAGR
Demand compounds through 2033, outpacing GDP across Device Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Device Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.73BLarge & growingTAM by 2033 at 4.4% CAGR
$653MServiceable nowreachable with today’s model
$120MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.35BBear2.9% CAGR
$1.73BBase4.4% CAGR
$2.22BBull5.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Technology optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Implant Device for AFib Treatment Market — a $4.44B market by 2033. Plan: grow share from 6.7% to 12.8%.
Market size · 2033$4.44Btotal addressable
Market CAGR7.7%2027–2033
Target share12.8%from 6.7% today
Revenue ambition$569Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.7% | 12.8% | Ahead |
| Revenue | $287M | $569M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 35.3% | 42.5% | On track |
| Customer retention | 85.1% | 96.7% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Device Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Technology capability
A defensible second engine — invest in Technology to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Device Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Technology
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $84M capacity & capability investment
- Greenlight bolt-on M&A in Technology
- Authorise North America expansion plan
- Fund R&D program for Device Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Implant Device for AFib Treatment Market conversation — a $5.83B market you can size, segment and defend in minutes.
Market size · 2033$5.83Btotal opportunity
Growth3.5%CAGR to 2033
Addressable buyers925+accounts in scope
Typical ROI5.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Device Type
Goal Grow share in Device Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.2×return on cost, year one
< 3 mopayback period
$61K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Abbott LaboratoriesBoston Scientific CorporationMedtronic plcBiosense Webster (a Johnson & Johnson company)LivaNova PLCMicroPort Scientific CorporationSorin Group (now part of LivaNova)Biotronik SE & Co. KG+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Implant Device for AFib Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Implant Device for AFib Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Implant Denture Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportImplant-Borne Prosthetics Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportImplantable Ventricular Assist Devices (VAD) Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportImplantable Ventricular Assist Devices Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportImplantable Venous Port Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportImplantable Textiles Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportImplantable Spinal Cord Stimulator System Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportImplantable Spinal Cord Stimulators Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportImplantable Spinal Cord Stimulation System Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportImplantable Spinal Cord Stimulation Device Market
Market size, share, segmentation and regional forecast.
$971M market · 2025 base year
View reportImplantable Ring Recorder Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportImplantable Remote Patient Monitoring Device Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.